BioStem Aligns with FDA’s Bayesian Clinical Trial Approach
In a randomized study of diabetic foot ulcers, BioStem’s BioRetain-processed allografts were reported to be nearly twice as likely...
Neomorph Doses First Patient in NEO-811 Cancer Trial
Neomorph has opened dosing in its first-in-human Phase 1/2 study of NEO-811, an oral, cereblon-dependent molecular glue degrader being...
Theriva to Present VCN-01 Retinoblastoma Trial Data at APAO
Theriva Biologics will present safety and clinical outcomes from an investigator-sponsored Phase 1 study of intravitreal VCN-01 (zabilugene almadenorepvec)...
BioCardia to Present Late-Breaking CardiAMP HF Trial Data
No efficacy or safety numbers were disclosed. BioCardia’s CardiAMP autologous cell therapy will be featured as a Late Breaking...
Arcutis’ Zoryve Cream: A Promising Trial for Infant Eczema
Fifty-eight percent of infants treated with roflumilast cream 0.05% achieved EASI-75 at Week 4 in an open-label Phase 2...
Successful Milestone for Actinogen’s Alzheimer’s Trial
An independent Data Monitoring Committee reviewed unblinded interim data from approximately 37% of Actinogen’s pivotal XanaMIA Alzheimer’s disease trial...
Successful 52-Week Phase 3 Acne Trial Data for ASC40
Denifanstat’s long-term safety profile in acne was clean in Ascletis’ open-label Phase 3 extension: among 240 patients treated once...
Landmark Study Reveals Molecular Roadmap of Brain Aging
141 living cortical samples from neurosurgical patients, paired with MRI and multi-omics profiling across more than 100,000 cells, revealed...
Successful Venglustat Phase 3 Trial Offers Hope for Gaucher
Sanofi’s brain-penetrant GCS inhibitor venglustat met the primary endpoint and three of four key secondary endpoints in the Phase...
Venglustat Breakthrough in Phase 3 Gaucher Disease Study
In the Phase 3 LEAP2MONO study (n=43), venglustat achieved statistically significant improvement in neurological function at week 52 versus...